On November 14, 2025, Bain Capital Life Sciences Investors, LLC disclosed a purchase of 520,310 shares of Cidara Therapeutics ...

Merck agreed to pay $9.2 billion to purchase Cidara Therapeutics, looking to cash in on the firm's experimental flu treatment.

Drugmakers are making notable deals, biotech is coming back, and much of the worry about tariffs and interest rates has faded ...

Biotech companies are making a solid comeback following an extended slump as investors shift their focus back to value and ...

Merck has announced plans to acquire Cidara Therapeutics for $9.2 billion, or $221.50 per share. Representing a heavy premium ...

Intellia Therapeutics also has fans on Wall Street. The company's current average price target of $32.3 (according to Yahoo! Finance) implies a significant 131% upside from its current levels. And ...

UroGen Pharma Ltd. (NASDAQ:URGN) is one of the best small-cap biotech stocks to buy according to analysts.

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 4 undervalued ...

The volatile biotech industry has done reasonably well so far in 2025 amid the ongoing tariff saga. Most pharma/biotech bigwigs are now investing heavily in manufacturing plants/operations in the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...

A biotech stock with strong FDA approval odds this November may see limited upside amid a full valuation and a pending lawsuit.

Legend Biotech (NASDAQ: LEGN) will release its quarterly earnings report on Wednesday, 2025-11-12. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Legend Biotech ...